Ferrante Dismisses Common Telemedicine-Cost Perceptions, Summarizes Senators’ Legislative Strategies
30 October 2017
Attorney TJ Ferrante was quoted in a MedPage Today article, “Telehealth Advocates Push for Expanded Use,” discussing why the perception that telemedicine will raise Medicare costs is inaccurate, and explaining why senators are floating multiple telemedicine bills – rather than just one – around Congress.
On the high-costs perception, Ferrante explained: “In 2016, Medicare spent about $28.7 million on telehealth services, and that might be a big number, but when it’s put into perspective, the overall Medicare budget is about $600-plus billion, so that’s an infinitesimal drop in the bucket … A lot of the concern that telehealth is going to cause costs [to skyrocket] isn’t based in reality.”
In conversation about the multiple bills floating around Congress, including the CONNECT Act and the CHRONIC Care Act, Ferrante said, “I think the approach this year is that they weren’t sure if one bill with all these bells and whistles was going to pass, so let’s have five, six or seven different pieces of legislation [that might get attached to bigger bills].”
On the high-costs perception, Ferrante explained: “In 2016, Medicare spent about $28.7 million on telehealth services, and that might be a big number, but when it’s put into perspective, the overall Medicare budget is about $600-plus billion, so that’s an infinitesimal drop in the bucket … A lot of the concern that telehealth is going to cause costs [to skyrocket] isn’t based in reality.”
In conversation about the multiple bills floating around Congress, including the CONNECT Act and the CHRONIC Care Act, Ferrante said, “I think the approach this year is that they weren’t sure if one bill with all these bells and whistles was going to pass, so let’s have five, six or seven different pieces of legislation [that might get attached to bigger bills].”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”